Condition: Actinic Keratosis (AK) · Sponsor: Thomas Dirschka
The aim of this study is to observe the influence of tirbanibulin on proliferation patterns of actinic keratoses (efficacy on proliferation score according to Schmitz et al.). For this purpose, tirbanibulin is applied in-label, proliferation is measured by LC-OCT at different time points and dermatohistopathology is performed (optionally) at the end. Local skin reactions to the product will also be recorded (tolerability).
This description comes directly from the study's public registry record.
Thomas Dirschka, Prof. Dr. med. · +49(0)20262933736 · T.dirschka@centroderm.de
Marcus Kuchner, Dr. med. · +49(0)20262933763 · m.kuchner@centroderm.de
Always discuss trial participation with your own doctor first.
| CentroDerm | Wuppertal, North Rhine-Westphalia, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06648447